Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc. (CYCC) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
cycc · stock forecast · 7 analysts (3M) · FMP · updated Nov 25, 2025
Analyst Rating & Consensus
Based on 7 Wall Street analysts in the past 3 months
Buy
7 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$1.00
Consensus
$1.00
-80.6% upside
Low
$1.00
Median: $1 · Last Close: $5.16
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $5.16 | ↓ 0.06% |
1-day model range: $5.11–$5.21. Peak: $5.21 (-0.06%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CYCC · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-05-03 | Roth MKM | Maintains | Buy→Buy |
| 2023-12-19 | Brookline Capital | Downgrade ↓ | Buy→Hold |
| 2023-12-19 | Roth MKM | Maintains | Buy→Buy |
| 2023-05-24 | Oppenheimer | Maintains | Outperform→Outperform |
| 2023-03-06 | Oppenheimer | Maintains | Outperform→Outperform |
| 2021-04-30 | Oppenheimer | Maintains | Outperform→Outperform |
| 2020-11-25 | JMP Securities | Downgrade ↓ | Market Outperform→Perform |
| 2020-11-25 | H.C. Wainwright | Maintains | Buy→Buy |
| 2020-11-25 | Roth Capital | Maintains | Buy→Buy |
| 2018-09-05 | Roth Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Cyclacel Pharmaceuticals, Inc. (CYCC) stock. Of the recent 15 rating actions, 0 were upgrades and 4 were downgrades. 7 analysts currently cover CYCC.
Analyst Recommendation Trends
CYCC analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 47.0% YoY
Revenue Next Year
$0M
↑ 88.7% YoY
EPS This Year
$-468.00
EPS Next Year
$-283.20
↓ 39.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast CYCC EPS of $-468.00 for the current fiscal year, based on estimates from 1 analysts. The CYCC revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CYCC stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CYCC price target is $1.00 (-80.6% upside), with an analyst consensus of Buy.
The CYCC short-term stock prediction for tomorrow is $5.16 (-0.06%).
Cyclacel Pharmaceuticals, Inc. trades on NASDAQ under the ticker CYCC. The CYCC stock outlook for 2027 is broadly positive, supported by a Buy consensus among 71% of covering analysts.
Frequently asked questions
CYCC forecast · 8 questionsAccording to 7 Wall Street analysts, the average 12-month CYCC price target is $1.00, with a high forecast of $1.00 and a low of $1.00. The median price target is shown in the chart above when available. This implies -80.6% potential upside from the current price of $5.16.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.